share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

Mangoceuticals | 4:持股變動聲明-高管 Cohen Jacob D.
美股SEC公告 ·  08/27 19:45

Moomoo AI 已提取核心訊息

Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
Jacob D. Cohen, CEO of Mangoceuticals, completed a transaction involving the company's common stock on August 26, 2024. The action, classified as a bona fide gift, consisted of both acquiring and disposing of 800,000 shares at no cost. Following the transaction, Cohen's direct holdings in Mangoceuticals common stock amounted to 9,075,000 shares.
曼果生物公司CEO Jacob D. Cohen於2024年8月26日完成了一筆涉及公司普通股的交易。此舉被歸類爲真正的禮物,包括無償獲取和處置80萬股。交易結束後,cohen在曼果生物公司的直接持股股數達到了907.5萬股。
曼果生物公司CEO Jacob D. Cohen於2024年8月26日完成了一筆涉及公司普通股的交易。此舉被歸類爲真正的禮物,包括無償獲取和處置80萬股。交易結束後,cohen在曼果生物公司的直接持股股數達到了907.5萬股。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息